Climate Change Data Portal
DOI | 10.1136/bmjopen-2023-077129 |
Climate footprint of industry-sponsored clinical research: an analysis of a phase-1 randomised clinical study and discussion of opportunities to reduce its impact | |
Laroche, Jason Keith; Alvarenga, Rodrigo; Collins, Michael; Costelloe, Thomas; De Soete, Wouter; Faludi, Jeremy; Rens, Kristel | |
发表日期 | 2024 |
ISSN | 2044-6055 |
起始页码 | 14 |
结束页码 | 1 |
卷号 | 14期号:1 |
英文摘要 | Objective This study aims to calculate the global warming potential, in carbon dioxide (CO2) equivalent emissions, from all in-scope activities involved in a phase-1 clinical study.Design Retrospective analysis.Data source Internal data held by Janssen Pharmaceuticals.Studies included Janssen-sponsored TMC114FD1HTX1002 study conducted between 2019 and 2021.Main outcome Measure CO2 equivalents (CO2e) for in-scope clinical trial activities calculated according to intergovernmental panel on climate change 2021 impact assessment methodology.Results The CO2e emissions generated by the trial were 17.65 tonnes. This is equivalent to the emissions generated by driving an average petrol-fueled family car 71 004 km or roughly 1.8 times around the circumference of the Earth. Commuting to the clinical site by the study participants generated the most emissions (5419 kg, 31% of overall emissions), followed by trial site utilities (2725 kg, 16% of overall emissions) and site staff travel (2560 kg, 15% of overall emissions). In total, the movement of people (participant travel, site staff travel and trial site staff travel) accounted for 8914 kg or 51% of overall trial emissions.Conclusions Decentralised trial models which seek to bring clinical trial operations closer to the participant offer opportunities to reduce participant travel. The electrification of sponsor vehicle fleets and society's transition towards electric vehicles may result in further reductions.Trial registration number NCT04208061. |
英文关键词 | Clinical Trial; Clinical trials; Health policy |
语种 | 英语 |
WOS研究方向 | General & Internal Medicine |
WOS类目 | Medicine, General & Internal |
WOS记录号 | WOS:001156806400007 |
来源期刊 | BMJ OPEN
![]() |
文献类型 | 期刊论文 |
条目标识符 | http://gcip.llas.ac.cn/handle/2XKMVOVA/296883 |
作者单位 | Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Delft University of Technology; Johnson & Johnson; Janssen Pharmaceuticals |
推荐引用方式 GB/T 7714 | Laroche, Jason Keith,Alvarenga, Rodrigo,Collins, Michael,et al. Climate footprint of industry-sponsored clinical research: an analysis of a phase-1 randomised clinical study and discussion of opportunities to reduce its impact[J],2024,14(1). |
APA | Laroche, Jason Keith.,Alvarenga, Rodrigo.,Collins, Michael.,Costelloe, Thomas.,De Soete, Wouter.,...&Rens, Kristel.(2024).Climate footprint of industry-sponsored clinical research: an analysis of a phase-1 randomised clinical study and discussion of opportunities to reduce its impact.BMJ OPEN,14(1). |
MLA | Laroche, Jason Keith,et al."Climate footprint of industry-sponsored clinical research: an analysis of a phase-1 randomised clinical study and discussion of opportunities to reduce its impact".BMJ OPEN 14.1(2024). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。